ANAHEIM, Calif., Sept. 30, 2014 -- Headquartered in Anaheim, California, WholeHealth Products. (OTC:GWPC) is a diversified company comprised of several specialized partners focused on leveraging the power and convenience of advanced technology and the proven expertise of its team of professionals to improve the fundamental business of health and wellness. WholeHealth Products' line of more than 10 professional diagnostic tests for hospitals, doctors, clinics and healthcare centers, and its more than 8 retail consumer tests is proud to announce an addition to its line of rapid diagnostic tests.
WholeHealth Products' R&D has discovered a specific enzyme which has a correlation to Autism and Fragile X. The quantitative amount of the enzyme is used to determine Autism or Fragile X in young children, as young as infants. This lab blood test is done using a microwell machine, giving the quantitative result; and the test can be done in less than 30 minutes. This revolutionary breakthrough will give parents a diagnosis they need at birth rather than waiting 3-4 years.
WholeHealth Products has already completed a Rapid Diagnostic version for this enzyme test, which can be used as a screening for Autism or Fragile X, giving a qualitative result in less than 5 minutes using no machines. WholeHealth Products will be seeking FDA marketing clearance for these new tests.
Inspired by its slogan, "Love Life Live Long," WholeHealth is committed to building long term relationships with the medical and healthcare professional and the patients, helping saves lives.
WholeHealth Products is your partner in the "Business of Science".
Certain information set forth in this fact sheet may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of WholeHealth Products Inc, including, but not limited to, risks associated with the impact of general economic conditions, industry conditions, dependence upon regulatory approvals, and the uncertainty of obtaining additional financing. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.Media Contact
Company Name: PublicWire
Contact Person: Dave Donlin
Address:5850 TG Lee Blvd, Suite 300
Country: United States